DeCure for Platelet abnormalities with eosinophilia and immune-mediated inflammatory disease
DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for platelet abnormalities with eosinophilia and immune-mediated inflammatory disease — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePlatelet abnormalities with eosinophilia and immune-mediated inflammatory disease maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for platelet abnormalities with eosinophilia and immune-mediated inflammatory disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
actin related protein 2/3 complex subunit 1B (ARPC1B) — ARPC1B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9I2B · 3.0 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Acquired platelet dysfunction with eosinophilia: A false premise
AbstractThe article by Shih et al.1Shih M.Y. Wang R.C. Liang C.W. Wang J.D. Acquired platelet dysfunction with eosinophilia in two patients.Pediatr Neonatol. 2020; 61: 346-347Abstract Full Text Full Text PDF PubMed Scopus (1) Google Scholar describing two cases of acquired platelet dysfunction with eosinophilia (APDE) raises an interesting syllogistic fallacy. Based on the two largest APDE series published by Laosombat et al.2Laosombat V. Wongchanchailert M. Sattayasevana B. Kietthubthew S. Wiriyasateinkul A. Acquired platelet dysfunction with eosinophilia in children in the south of Thailand.Platelets. 2001; 12: 5-14Crossref PubMed Scopus (17) Google Scholar and Chotsampancharoen et al.,3Chotsampancharoen T. Sripornsawan P. Duangchu S. McNeil E. Clinical course and outcome of childhood acquired platelet dysfunction with eosinophilia.Acta Haematol. 2018; 139: 28-32Crossref PubMed Scopus (7) Google Scholar the authors boldly summarized three APDE elements for diagnosis: abnormal bleeding, eosinophilia, and platelet dysfunction. It follows that if eosinophilia is an essential element for diagnosis, then both studies published by Laosombat et al. and Chotsampancharoen et al. have to be disqualified. This is because in the former series, 23 of the 168 (14%) patients did not have eosinophilia.2Laosombat V. Wongchanchailert M. Sattayasevana B. Kietthubthew S. Wiriyasateinkul A. Acquired platelet dysfunction with eosinophilia in children in the south of Thailand.Platelets. 2001; 12: 5-14Crossref PubMed Scopus (17) Google Scholar In addition, Chotsampancharoen et al. did not specify the number of patients who had eosinophilia in their study. However, based on their published data with a mean eosinophil count of 3.0 × 109/L and standard deviation of 2.1,3Chotsampancharoen T. Sripornsawan P. Duangchu S. McNeil E. Clinical course and outcome of childhood acquired platelet dysfunction with eosinophilia.Acta Haematol. 2018; 139: 28-32Crossref PubMed Scopus (7) Google Scholar it can be deduced that 9 (13%) of the 69 cases had eosinophil counts below 0.5 × 109/L. However, if the two largest APDE series are invalid, then proposed defining elements of APDE Shih et al. will be baseless. The only explanation for this fallacy is that APDE as a disease entity is a false premise. Nevertheless, I believe that the cases reported Shih et al. are a valid entity that are similar to those defined under idiopathic purpura with gray platelets (IPGP).4Lee A.C. Idiopathic purpura with gray platelets: an acquired form of gray platelet syndrome.J Pediatr Hematol Oncol. 2019; 41: 47-50Crossref PubMed Scopus (2) Google Scholar Gray platelets are an uncommon feature in routine hematomorphology and can be easily missed by the unprepared examiner. However, it is the simplest way of identifying platelet dysfunction in this disease entity, and the result is immediate. The diagnosis of IPGP can be made before the patient walks away from the consultation room at the first visit. It is often said that APDE is a disease of Southeast Asia, but Thailand is not the only country there. Yet, most of the reported cases of APDE in the literature originated from Thailand. Case reports from elsewhere simply followed what the name of APDE implies and reinforced the internal logic of the syllogistic fallacy. Non-conforming clinical and laboratory features such as the absence of eosinophilia at diagnosis, persistence of eosinophilia upon resolution of the bleeding tendency, and absence of intestinal parasite infections are more significant factors in defining what the non-essential elements are in the clinical diagnosis. Our understanding of this unique childhood bleeding disorder can only be advanced if we can look at the data critically and define its clinical and laboratory features more precisely in a more replicable way. None.
Biomedical Research and Therapy · 2024 · 1 citations · open access
Acquired Platelet Dysfunction with Eosinophilia: A Case Series
AbstractBackground: Acquired platelet dysfunction with eosinophilia (APDE) is characterized by a temporary impairment in platelet function accompanied by significant eosinophilia. This condition, also known as "non-thrombocytopenic purpura with eosinophilia," primarily affects children in the South-East Asian region, presenting as a bleeding disorder. Case Presentation: In this case series, we report on three patients who were admitted to our hospital displaying skin bruising, despite being previously healthy, with no history of drug use or recent travel. These patients exhibited classic signs of APDE, and interestingly, some showed spontaneous recovery without the need for medical intervention. Diagnostic evaluations revealed an increased eosinophil count, whereas the basic hemostatic parameters and platelet counts remained within normal limits. However, platelet aggregation studies indicated abnormalities. Conclusion: It is crucial to identify this benign disorder promptly, as providing reassurance to patients and their families plays a critical role in the management of APDE.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
